Neurol India Close
 

Figure 1: (a) Adenocarcinoma, moderately differentiated. (b–d) IHC: retained staining for MSH2, MSH6, and MLH1. (e) PMS2: lost in both tumor (arrow) and adjacent normal tissue (dotted arrow). (f) Glioblastoma (Inset: IHC GFAP). (g) IHC: retained staining MLH1 (MSH2, MSH6 not shown). (h) PMS2: lost in both tumor and admixed blood vessels and normal glial cells. (i) Mutational signatures (glioblastoma): 6, 15, 10. (j) Mutational signatures (adenocarcinoma): 15, 28. (k) Initial diagnosis. (l) First relapse. (m) Immune flare. (n) Response. (o) True progression

Figure 1: (a) Adenocarcinoma, moderately differentiated. (b–d) IHC: retained staining for MSH2, MSH6, and MLH1. (e) PMS2: lost in both tumor (arrow) and adjacent normal tissue (dotted arrow). (f) Glioblastoma (Inset: IHC GFAP). (g) IHC: retained staining MLH1 (MSH2, MSH6 not shown). (h) PMS2: lost in both tumor and admixed blood vessels and normal glial cells. (i) Mutational signatures (glioblastoma): 6, 15, 10. (j) Mutational signatures (adenocarcinoma): 15, 28. (k) Initial diagnosis. (l) First relapse. (m) Immune flare. (n) Response. (o) True progression